Oncolytic Virotherapy and Microenvironment in Multiple Myeloma

Area of Science:

• Hematologic Malignancies
• Cancer Therapy
• Immunology

Background:

• Multiple myeloma (MM) is a plasma cell malignancy dependent on the bone marrow microenvironment.
• Despite advancements, MM patients frequently relapse and develop treatment resistance.
• Novel therapeutic strategies targeting both myeloma cells and their microenvironment are crucial.

Purpose of the Study:

• To review the mechanisms of oncolytic viruses in targeting MM cells and the microenvironment.
• To discuss the potential of oncolytic virotherapy, including non-human viruses, for MM treatment.
• To explore combination therapies of oncolytic viruses with existing MM treatments.

Main Methods:

• Review of preclinical and clinical studies on oncolytic viruses in MM models.
• Analysis of direct and indirect mechanisms of oncolytic viruses against MM.
• Evaluation of combination strategies involving oncolytic virotherapy and other anti-MM drugs.

Main Results:

• Oncolytic viruses demonstrate tumor-specific lysis and immune system activation against MM.
• Non-human viruses may circumvent pre-existing anti-viral immunity, enhancing therapeutic efficacy.
• Combination therapies show potential for improved anti-MM responses by targeting both tumor and microenvironment.

Conclusions:

• Oncolytic virotherapy is a promising strategy for overcoming MM treatment resistance.
• Targeting both MM cells and the bone marrow microenvironment is key for effective treatment.
• Further investigation into oncolytic virus combinations is warranted for improved MM patient outcomes.